Skip to main content
. 2014 Apr 23;5(8):2030–2043. doi: 10.18632/oncotarget.1918

Figure 6. MDM2 Inhibition and MAPK Pathway Inhibition Cooperatively Suppress RKO Tumor Xenograft Growth.

Figure 6

(A) RKO tumor-bearing mice were treated with vehicle, 100 mg/kg AMG 232 (MDM2 inhibitor) or 10 mg/kg C-1 (BRAF inhibitor) alone or in combination, or with (B) vehicle, 100 mg/kg AMG 232 or 10 mg/kg PD0325901 (MEK inhibitor) alone or in combination. Data are represented as mean tumor volumes, and error bars represent SEM (n=10 mice/group). *p < 0.0001 combination groups vs. single agents by factorial RMANOVA followed by Dunnett's post hoc analysis for repeated measurements.